The highs and lows of venetoclax with hypomethylating agents for refractory AML

被引：0
|
作者：
Brunner, Andrew M. [1 ]
机构：
[1] Massachusetts Gen Hosp, Zero Emerson Pl,Suite 118, Boston, MA 02114 USA
来源：
LEUKEMIA RESEARCH | 2020年 / 91卷
关键词：
Acute myeloid leukemia; Venetoclax; Azacitidine; Decitabine;
D O I：
10.1016/j.leukres.2020.106320
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML
    Ucar, M. A.
    Ozet, G.
    Koyuncu, M. B.
    Sonmez, M.
    Akidan, O.
    Ayli, M.
    Yildirim, M.
    Pehlivan, M.
    Akkurt, D. M.
    Sahin, H.
    Guvenc, B.
    Okan, V
    Tiftik, E. N.
    Akdeniz, A.
    Dincyurek, H. D.
    Gunes, A. K.
    Dagdas, S.
    Acar, H., I
    Ucar, H. K.
    Tombak, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (21) : 6557 - 6565
  • [2] Healthcare Disparities Among Minorities Treated with Venetoclax and Hypomethylating Agents in AML
    Bouligny, Ian M.
    Murray, Graeme
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Alnimer, Yanal
    Zacholski, Kyle
    Venn, Chad
    Maher, Keri
    BLOOD, 2022, 140 : 13305 - 13306
  • [3] Results of Treatment With Hypomethylating Agents Versus Hypomethylating Agents/Venetoclax in Patients With AML Single-Center Experience
    Patino, Ana Flavia
    Brulc, Erika
    Conca, Alberto Gimenez
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S289 - S289
  • [4] Efficacy of Hypomethylating Agents with Venetoclax in TP53mut AML
    Bouligny, Ian M.
    Murray, Graeme
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Alnimer, Yanal
    Zacholski, Kyle
    Venn, Chad
    Maher, Keri
    BLOOD, 2022, 140 : 11842 - 11843
  • [5] Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
    Liu, Yifan
    Li, Yanfen
    Zhang, Ran
    Yu, Zhangyu
    Jing, Yu
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [6] Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting
    Nanni, Jacopo
    Papayannidis, Cristina
    Cristiano, Gianluca
    Marconi, Giovanni
    Sartor, Chiara
    Parisi, Sarah
    Ottaviani, Emanuela
    Baldini, Lorenza
    Testoni, Nicoletta
    Baldazzi, Carmen
    Ricci, Paolo
    Bezzi, Chiara Di Giovanni
    Abd-alatif, Rania
    Paolini, Stefania
    Cavo, Michele
    Curti, Antonio
    BLOOD, 2020, 136
  • [7] Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM
    Huemer, Florian
    Melchardt, Thomas
    Jansko, Bettina
    Wahida, Adam
    Jilg, Stefanie
    Jost, Philipp J.
    Klieser, Eckhard
    Steiger, Katja
    Magnes, Teresa
    Pleyer, Lisa
    Greil-Ressler, Sigrun
    Rass, Christof
    Greil, Richard
    Egle, Alexander
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (05) : 437 - 441
  • [8] Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting
    Jeffrey, Lantz, Jr.
    Pham, Natalie
    Jones, Caroline
    Kundu, Debamita
    McCann, Nicholas
    El Chaer, Firas
    Reed, Daniel
    Keng, Michael
    BLOOD, 2023, 142
  • [9] Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents
    Othman, Tamer A.
    Mei, Matthew
    Zhang, Jianying
    Aldoss, Ibrahim
    Stein, Anthony
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : E140 - E143
  • [10] Molecular stratification of response and survival of venetoclax in combination with hypomethylating agents in AML.
    Maher, Keri Renee
    Bouligny, Ian Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345